Exagen Inc. (NASDAQ:XGN) Q1 2023 Earnings Conference Call May 15, 2023 4:30 AM ET
Company Participants
Ryan Douglas - Investor Relations
John Aballi - President & Chief Executive Officer
Kamal Adawi - Chief Financial Officer
Conference Call Participants
Kyle Mikson - Canaccord
Dan Brennan - TD Cowen
Paul Knight - KeyBanc
Operator
Good day, ladies and gentlemen, and welcome to the Exagen Q1 2023 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Ryan Douglas of Investor Relations. Please go ahead.
Ryan Douglas
Good afternoon and thank you for joining us today. Earlier today, Exagen Inc. released financial results for the quarter ended March 31st, 2023. The release is currently available on the company's website at www.exagen.com. John Aballi, President and Chief Executive Officer; and Kamal Adawi, Chief Financial Officer, will host this afternoon's call.
Before we get started, I would like to remind everyone that management will be making statements during this call that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.
Any statements contained in this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including, without limitation, statements regarding our business strategy and future financial and operating performance, including guidance for the ended June 30th, 2023, potential profitability, our current and future product offerings, and reimbursement and coverage are based upon current estimates and various assumptions.
These statements involve material risks and uncertainties that could cause actual results to differ materially from those anticipated or implied by these forward-looking statements.
Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with the business, please see our filings with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2022 and subsequent filings.
The information provided in this conference call speaks only to the live broadcast today, May 15th, 2023. Exagen disclaims any intention or obligation, except as required by law, to update or revise any information, financial projections or other forward-looking statements, whether because of new information, future events, or otherwise.
I will now turn the call over to John Aballi, President and CEO of Exagen.